Roche gets accelerated U.S. approval for lung cancer drug
U.S. health regulators on Friday said they have granted accelerated approval to Roche Holding's drug for advanced lung cancer in patients with a specific genetic mutation.The drug, alectinib, to be sold under the brand name Alecensa, was approved to treat patients with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate,...
The drug, alectinib, to be sold under the brand name Alecensa, was approved to treat patients with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate, treatment with Pfizer's Xalkori.
"Today's approval provides a new therapy for a group of patients who would have few treatment options once their disease no longer responds to treatment with Xalkori," Richard Pazdur, head of the Food and Drug Administration's Hematology and Oncology Products division, said in a statement.
Xalkori was seen as an advance in the field of personalized medicine as it was designed to treat only patients with the ALK genetic mutation, which account for about 4 percent of NSCLC patients. Pfizer is also developing a drug for ALK positive patients who have stopped responding to Xalkori.
The FDA's Accelerated Approval Program allows conditional approval of a medicine that fills an unmet medical need for a serious condition based on early evidence of clinical benefit.
A confirmatory study is required to verify the benefit of Alecensa for it to gain full approval, the agency said. (Reporting by Bill Berkrot; Editing by David Gregorio)
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country.She is a member of the Association of Healthcare Journalists. She can be contacted at firstname.lastname@example.org. Contact no. 011-43720751